The case for pathogen inactivation of blood components

被引：3
|
作者：
Sandler, SG [1 ]
机构：
[1] Georgetown Univ Hosp, Dept Lab Med, Washington, DC 20007 USA
来源：
CURRENT OPINION IN HEMATOLOGY | 2005年 / 12卷 / 06期
关键词：
D O I：
10.1097/01.moh.0000177832.70657.33
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：471 / 472
页数：2
相关论文
共 50 条
  • [31] Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use
    Osselaer, Jean Claude
    Doyen, Chantal
    Defoin, Laurence
    Debry, Cecile
    Goffaux, Maite
    Messe, Nathalie
    Van Hooydonk, Maryse
    Bosly, Andre
    Lin, Jin Sying
    Lin, Lily
    Corash, Laurence
    [J]. TRANSFUSION, 2009, 49 (07) : 1412 - 1422
  • [32] PATHOGEN INACTIVATION AND IN VITRO FUNCTION OF PLATELET COMPONENTS COLLECTED IN 100% PLASMA TREATED WITH INTERCEPT BLOOD SYSTEM™
    Lin, L.
    Liu, W.
    Shimosaka, A.
    Osselaer, J. C.
    [J]. VOX SANGUINIS, 2009, 97 : 106 - 106
  • [33] INACTIVATION OF MICROBIAL CONTAMINANTS OF BLOOD COMPONENTS
    AUBUCHON, JP
    DODD, RY
    [J]. CLINICS IN LABORATORY MEDICINE, 1992, 12 (04) : 787 - 803
  • [34] Whole Blood Treated with Riboflavin/UV Light: Recombination of Blood Components to Modulate the Pathogen Inactivation Impact on its Hemostatic Function
    Arbaeen, A. F.
    Schubert, P.
    Culibrk, C.
    Devine, D.
    [J]. TRANSFUSION, 2016, 56 : 58A - 58A
  • [35] PHOTODYNAMIC VIRUS INACTIVATION OF BLOOD COMPONENTS
    MOHR, H
    LAMBRECHT, B
    SELZ, A
    [J]. IMMUNOLOGICAL INVESTIGATIONS, 1995, 24 (1-2) : 73 - 85
  • [36] Clinical Experience with Pathogen Inactivation of Platelet Components for Transfusion Support
    Cazenave, Jean-Pierre
    Waller, Chantal
    Mendel, Isabelle
    Kientz, Daniel
    Kande, Gerard
    Raidot, Jean-Pierre
    Wiesel, Marie-Louise
    Laforet, Michel
    Isola, Herve
    [J]. PROGRESS AND CHALLENGES IN TRANSFUSION MEDICINE, HEMOSTASIS AND HEMOTHERAPY: STATE OF THE ART 2008, 2008, : 248 - 263
  • [37] The hemostatic efficacy of platelet components prepared with pathogen inactivation reply
    Vamvakas, Eleftherios C.
    [J]. TRANSFUSION, 2011, 51 (06) : 1356 - 1359
  • [38] THERAFLEX ultraviolet C (UVC)-based pathogen reduction technology for bacterial inactivation in blood components: advantages and limitations
    Schulze, Torsten J.
    Gravemann, Ute
    Seltsam, Axel
    [J]. ANNALS OF BLOOD, 2022, 7
  • [39] The Economic Impact of Pathogen Inactivation in the Blood Center and Hospital
    McCullough, J.
    Stowell, C.
    Gorlin, J. B.
    Ward, D.
    Goldfinger, D.
    Sandhu, H.
    Chrebtow, V.
    Stassinopoulos, A.
    [J]. TRANSFUSION, 2014, 54 : 57A - 57A
  • [40] Viral inactivation of blood components: Recent advances
    Horowitz, B
    BenHur, E
    [J]. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 1996, 3 (01) : 75 - 77
12345